

# Protocol

## Autologous Chondrocyte Implantation for Focal Articular Cartilage Lesions

(70148)

<b>Medical Benefit</b>		<b>Effective Date:</b> 01/01/14	<b>Next Review Date:</b> 07/15
<b>Preauthorization</b>	Yes	<b>Review Dates:</b> 02/07, 02/08, 03/09, 01/10, 01/11, 09/11, 09/12, 09/13, 07/14	

*The following Protocol contains medical necessity criteria that apply for this service. It is applicable to Medicare Advantage products unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. **Preauthorization is required.** Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.*

### Description

A variety of procedures are being developed to resurface articular cartilage defects. Autologous chondrocyte implantation (ACI) involves harvesting chondrocytes from healthy tissue, expanding the cells in vitro, and implanting the expanded cells into the chondral defect under a periosteal or fibrin patch. Second- and third-generation techniques include combinations of autologous chondrocytes, scaffolds, and growth factors.

### Background

Damaged articular cartilage typically fails to heal on its own and can be associated with pain, loss of function, and disability and may lead to debilitating osteoarthritis over time. These manifestations can severely impair an individual's activities of daily living and adversely affect quality of life. Conventional treatment options include debridement, subchondral drilling, microfracture, and abrasion arthroplasty. Debridement involves the removal of synovial membrane, osteophytes, loose articular debris, and diseased cartilage and is capable of producing symptomatic relief. Subchondral drilling, microfracture, and abrasion arthroplasty attempt to restore the articular surface by inducing the growth of fibrocartilage into the chondral defect. Compared to the original hyaline cartilage, fibrocartilage has less capability to withstand shock or shearing force and can degenerate over time, often resulting in the return of clinical symptoms. Osteochondral grafts and autologous chondrocyte implantation (ACI) attempt to regenerate hyaline-like cartilage and thereby restore durable function. Osteochondral grafts for the treatment of articular cartilage defects are discussed in a separate Protocol.

With autologous chondrocyte implantation, a region of healthy articular cartilage is identified and biopsied through arthroscopy. The tissue is sent to a facility licensed by the U.S. Food and Drug Administration (FDA) where it is minced and enzymatically digested, and the chondrocytes are separated by filtration. The isolated chondrocytes are cultured for 11–21 days to expand the cell population, tested, and then shipped back for implantation. With the patient under general anesthesia, an arthrotomy is performed, and the chondral lesion is excised up to the normal surrounding cartilage. A periosteal flap is removed from the proximal medial tibia and sutured to the surrounding rim of normal cartilage. The cultured chondrocytes are then injected beneath the periosteal flap. ACI may be considered more effective for larger lesions than microfracture or osteochondral grafts, but it is technically difficult, requiring two procedures and harvesting of periosteum. In addition, use of the FDA-indicated periosteal cover may result in hypertrophy, as well as donor-site morbidity.

Methods to improve the ACI procedure are being investigated, including the use of a scaffold or matrix-induced ACI (MACI) composed of biocompatible carbohydrates, protein polymers, or synthetics. Desired features of articular cartilage repair procedures are the ability to: 1) be implanted easily, 2) reduce surgical morbidity, 3) not require harvesting of other tissues, 4) enhance cell proliferation and maturation, 5) maintain the phenotype,

and 6) integrate with the surrounding articular tissue. In addition to the potential to improve the formation and distribution of hyaline cartilage, use of a scaffold with MACI eliminates the need for harvesting and suture of a periosteal patch. A scaffold without cells may also support chondrocyte growth.

#### *Regulatory Status*

The culturing of chondrocytes is considered by the FDA to fall into the category of manipulated autologous structural (MAS) cells, which are subject to a biologic licensing requirement. At the present time, only Carticel™ (Genzyme) has received FDA approval for the culturing of chondrocytes through a biologics license. In 1997, Carticel received FDA approval for the repair of clinically significant, "...symptomatic cartilaginous defects of the femoral condyle (medial lateral or trochlear) caused by acute or repetitive trauma...." The labeled indication was revised in October 1999 to read as follows:

"Carticel is indicated for the repair of symptomatic cartilaginous defects of the femoral condyle (medial, lateral, or trochlear), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure." Thus, the revised labeling suggests a more restricted use of autologous chondrocytes, i.e., as a second-line therapy after failure of initial arthroscopic or surgical repair.

"Carticel is not indicated for the treatment of cartilage damage associated with osteoarthritis. Carticel should only be used in conjunction with debridement, placement of a periosteal flap and rehabilitation. The independent contributions of the autologous cultured chondrocytes and other components of the therapy to outcome are unknown. Data regarding functional outcomes beyond three years of autologous cultured chondrocyte treatment are limited."

A number of second-generation methods for implanting autologous chondrocytes in a biodegradable matrix are currently in development/testing or are available only outside of the U.S. These include Atelocollagen (collagen gel, Koken), BioCart II (ProChon Biotech, Phase II trial), Bioseed C (polymer scaffold, BioTissue Technologies) CaReS (collagen gel, Ars Arthro), Cartilix (polymer hydrogel, Biomet), Cartipatch (solid scaffold with an agarose-alginate matrix, TBF Tissue Engineering, Phase III trial), Chondron (fibrin gel, Sewon Cellontech), Hyalograft C (hyaluronic acid-based scaffold, Fidia Advanced Polymers), MACI® (matrix-induced ACI, Verigen and Genzyme, a Sanofi Company, available outside of the U.S.), NeoCart (ACI with a three-dimensional chondromatrix, Histogenics, Phase III trial), and Novocart®3D (collagen-chondroitin sulfate scaffold, Aesculap Biologics, Phase III trial). ChondroSelect (characterized chondrocyte implantation, TiGenex, Phase III trial completed) uses a gene marker profile to determine in vivo cartilage-forming potential and thereby optimizes the phenotype (e.g., hyaline cartilage vs. fibrocartilage) of the tissue produced with each ACI implantation cell batch. Each batch of chondrocytes is graded based on the quantitative gene expression of a selection of positive and negative markers for hyaline cartilage formation. Although clinical use of these second-generation ACI products has been reported in Europe and Asia, none are approved for use in the U.S. at this time.

#### *Related Protocols*

Continuous Passive Motion (CPM) in the Home Setting

Meniscal Allografts and Other Meniscal Implants

Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Orthopedic Applications of Stem-Cell Therapy

#### **Policy (Formerly Corporate Medical Guideline)**

Autologous chondrocyte implantation may be considered **medically necessary** for the treatment of disabling full thickness articular cartilage defects of the knee caused by acute or repetitive trauma, in patients who have had

an inadequate response to a prior surgical procedure, when all of the following criteria are met:

- Adolescent patients should be skeletally mature with documented closure of growth plates (e.g., 15 years or older). Adult patients should be too young to be considered an appropriate candidate for total knee arthroplasty or other reconstructive knee surgery (e.g., younger than 55 years).
- Focal, full thickness (grade III or IV) unipolar lesions on the weight bearing surface of the femoral condyles or trochlea at least 1.5 cm<sup>2</sup> in size
- Documented minimal to absent degenerative changes in the surrounding articular cartilage (Outerbridge Grade II or less), and normal-appearing hyaline cartilage surrounding the border of the defect
- Normal knee biomechanics, or alignment and stability achieved concurrently with autologous chondrocyte implantation

Autologous chondrocyte implantation for all other joints, including patellar and talar, and any indications other than those listed above is considered **investigational**.

Matrix-induced autologous chondrocyte implantation is considered **investigational**.

### Policy Guidelines

For smaller lesions (e.g., smaller than 4cm<sup>2</sup>) if debridement is the only prior surgical treatment, then consideration should be given to marrow-stimulating techniques before autologous chondrocyte implantation (ACI) is performed.

The average defect size reported in the literature is about 5 cm<sup>2</sup>; many studies treated lesions as large as 15 cm<sup>2</sup>.

Severe obesity, e.g., body mass index greater than 35 kg/m<sup>2</sup>, may affect outcomes due to the increased stress on weight bearing surfaces of the joint.

Misalignment and instability of the joint are contraindications. Therefore additional procedures, such as repair of ligaments or tendons or creation of an osteotomy for realignment of the joint, may be performed at the same time. In addition, meniscal allograft transplantation may be performed in combination, either concurrently or sequentially, with ACI. The charges for the culturing component of the procedure are submitted as part of the hospital bill.

The entire ACI procedure consists of four steps: 1) the initial arthroscopy and biopsy of normal cartilage, 2) culturing of chondrocytes, 3) a separate arthrotomy to create a periosteal flap and implant the chondrocytes, and 4) post-surgical rehabilitation. The initial arthroscopy may be scheduled as a diagnostic procedure; as part of this procedure, a cartilage defect may be identified, prompting biopsy of normal cartilage in anticipation of a possible chondrocyte transplant. The biopsied material is then sent for culturing and returned to the hospital when the implantation procedure (i.e., arthrotomy) is scheduled.

---

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this Protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

## References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Autologous chondrocyte transplantation. TEC Assessments 1996; Volume 11, Tab 8.
2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Autologous chondrocyte transplantation. TEC Assessments 1997; Volume 12, Tab 26.
3. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Autologous chondrocyte transplantation. TEC Assessments 2000; Volume 15, Tab 12.
4. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Autologous chondrocyte transplantation of the knee. TEC Assessments 2003; Volume 18, Tab 2.
5. Harris JD, Cavo M, Brophy R et al. Biological Knee Reconstruction: A Systematic Review of Combined Meniscal Allograft Transplantation and Cartilage Repair or Restoration. *Arthroscopy* 2011; 27(3):409-18.
6. Mithoefer K, McAdams T, Williams RJ et al. Clinical efficacy of the microfracture technique for articular cartilage repair in the knee: an evidence-based systematic analysis. *Am J Sports Med* 2009; 37(10):2053-63.
7. Knutsen G, Engebretsen L, Ludvigsen TC et al. Autologous chondrocyte implantation compared with microfracture in the knee. A randomized trial. *J Bone Joint Surg Am* 2004; 86-A(3):455-64.
8. Knutsen G, Drogset JO, Engebretsen L et al. A randomized trial comparing autologous chondrocyte implantation with microfracture. Findings at five years. *J Bone Joint Surg Am* 2007; 89(10):2105-12.
9. Visna P, Pasa L, Cizmar I et al. Treatment of deep cartilage defects of the knee using autologous chondrograft transplantation and by abrasive techniques--a randomized controlled study. *Acta Chir Belg* 2004; 104(6):709-14.
10. Horas U, Pelinkovic D, Herr G et al. Autologous chondrocyte implantation and osteochondral cylinder transplantation in cartilage repair of the knee joint. A prospective, comparative trial. *J Bone Joint Surg Am* 2003; 85-A(2):185-92.
11. Bentley G, Biant LC, Carrington RW et al. A prospective, randomised comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects in the knee. *J Bone Joint Surg Br* 2003; 85(2):223-30.
12. Bentley G, Biant LC, Vijayan S et al. Minimum ten-year results of a prospective randomised study of autologous chondrocyte implantation versus mosaicplasty for symptomatic articular cartilage lesions of the knee. *J Bone Joint Surg Br* 2012; 94(4):504-9.
13. Dozin B, Malpeli M, Cancedda R et al. Comparative evaluation of autologous chondrocyte implantation and mosaicplasty: a multicentered randomized clinical trial. *Clin J Sport Med* 2005; 15(4):220-6.
14. Cole B, Brewster R, DeBerardino T et al. Improvement in Symptoms and Function after Autologous Chondrocyte Implantation (ACI, Carticel®) in Patients who Failed Prior Treatment, Results of the Study of Treatment of Articular Repair (STAR). AOSM 2007. Available online at: <http://www.sportsmed.org/tabs/education/downloads/AM2007%20Final%20Abstracts.pdf>. Last accessed February, 2011.
15. Genzyme Biosurgery. Caritcel prescribing information. 2007. Available online at: [http://www.genzymebiosurgery.com/pdfs/carticel\\_package\\_insert.pdf](http://www.genzymebiosurgery.com/pdfs/carticel_package_insert.pdf). Last accessed February, 2011.

16. Zaslav K, Cole B, Brewster R et al. A prospective study of autologous chondrocyte implantation in patients with failed prior treatment for articular cartilage defect of the knee: results of the Study of the Treatment of Articular Repair (STAR) clinical trial. *Am J Sports Med* 2009; 37(1):42-55.
17. Gooding CR, Bartlett W, Bentley G et al. A prospective, randomised study comparing two techniques of autologous chondrocyte implantation for osteochondral defects in the knee: Periosteum covered versus type I/III collagen covered. *Knee* 2006; 13(3):203-10.
18. Pestka JM, Bode G, Salzmann G et al. Clinical outcome of autologous chondrocyte implantation for failed microfracture treatment of full-thickness cartilage defects of the knee joint. *Am J Sports Med* 2012; 40(2):325-31.
19. Vanlauwe J, Saris DB, Victor J et al. Five-year outcome of characterized chondrocyte implantation versus microfracture for symptomatic cartilage defects of the knee: early treatment matters. *Am J Sports Med* 2011; 39(12):2566-74.
20. Minas T, Gomoll AH, Rosenberger R et al. Increased failure rate of autologous chondrocyte implantation after previous treatment with marrow stimulation techniques. *Am J Sports Med* 2009; 37(5):902-8.
21. Browne JE, Anderson AF, Arciero R et al. Clinical outcome of autologous chondrocyte implantation at 5 years in U.S. subjects. *Clin Orthop Relat Res* 2005; (436):237-45.
22. Moseley JB, Jr., Anderson AF, Browne JE et al. Long-term durability of autologous chondrocyte implantation: a multicenter, observational study in U.S. patients. *Am J Sports Med* 2010; 38(2):238-46.
23. Minas T, Von Keudell A, Bryant T et al. The John Insall Award: A minimum 10-year outcome study of autologous chondrocyte implantation. *Clin Orthop Relat Res* 2014; 472(1):41-51.
24. Peterson L, Vasiliadis HS, Brittberg M et al. Autologous chondrocyte implantation: a long-term follow-up. *Am J Sports Med* 2010; 38(6):1117-24.
25. Rosenberger RE, Gomoll AH, Bryant T et al. Repair of large chondral defects of the knee with autologous chondrocyte implantation in patients 45 years or older. *Am J Sports Med* 2008; 36(12):2336-44.
26. Niemeyer P, Pestka JM, Kreuz PC et al. Characteristic complications after autologous chondrocyte implantation for cartilage defects of the knee joint. *Am J Sports Med* 2008; 36(11):2091-9.
27. Henderson IJ, Lavigne P. Periosteal autologous chondrocyte implantation for patellar chondral defect in patients with normal and abnormal patellar tracking. *Knee* 2006; 13(4):274-9.
28. Farr J. Autologous chondrocyte implantation improves patellofemoral cartilage treatment outcomes. *Clin Orthop Relat Res* 2007; 463:187-94.
29. Gomoll AH, Gillogly SD, Cole BJ et al. Autologous chondrocyte implantation in the patella: a multicenter experience. *Am J Sports Med* 2014; 42(5):1074-81.
30. Pascual-Garrido C, Slabaugh MA, L'Heureux DR et al. Recommendations and treatment outcomes for patellofemoral articular cartilage defects with autologous chondrocyte implantation: prospective evaluation at average 4-year follow-up. *Am J Sports Med* 2009; 37 Suppl 1:33S-41S.
31. Niemeyer P, Steinwachs M, Erggelet C et al. Autologous chondrocyte implantation for the treatment of retropatellar cartilage defects: clinical results referred to defect localisation. *Arch Orthop Trauma Surg* 2008; 128(11):1223-31.

32. Gobbi A, Kon E, Berruto M et al. Patellofemoral full-thickness chondral defects treated with second-generation autologous chondrocyte implantation: results at 5 years' follow-up. *Am J Sports Med* 2009; 37(6):1083-92.
33. Gigante A, Enea D, Greco F et al. Distal realignment and patellar autologous chondrocyte implantation: mid-term results in a selected population. *Knee Surg Sports Traumatol Arthrosc* 2009; 17(1):2-10.
34. Filardo G, Kon E, Andriolo L et al. Treatment of "patellofemoral" cartilage lesions with matrix-assisted autologous chondrocyte transplantation: a comparison of patellar and trochlear lesions. *Am J Sports Med* 2014; 42(3):626-34.
35. Farr J, Rawal A, Marberry KM. Concomitant meniscal allograft transplantation and autologous chondrocyte implantation: minimum 2-year follow-up. *Am J Sports Med* 2007; 35(9):1459-66.
36. Rue JP, Yanke AB, Busam ML et al. Prospective evaluation of concurrent meniscus transplantation and articular cartilage repair: minimum 2-year follow-up. *Am J Sports Med* 2008; 36(9):1770-8.
37. Nawaz SZ, Bentley G, Briggs TWR et al. Autologous chondrocyte implantation in the knee. *J Bone Joint Surg Am* 2014; 96(10):824-30.
38. Minas T, Gomoll AH, Solhpour S et al. Autologous chondrocyte implantation for joint preservation in patients with early osteoarthritis. *Clin Orthop Relat Res* 2010; 468(1):147-57.
39. Zengerink M, Struijs PA, Tol JL et al. Treatment of osteochondral lesions of the talus: a systematic review. *Knee Surg Sports Traumatol Arthrosc* 2010; 18(2):238-46.
40. Choi WJ, Park KK, Kim BS et al. Osteochondral lesion of the talus: is there a critical defect size for poor outcome? *Am J Sports Med* 2009; 37(10):1974-80.
41. Niemeyer P, Salzmänn G, Schmal H et al. Autologous chondrocyte implantation for the treatment of chondral and osteochondral defects of the talus: a meta-analysis of available evidence. *Knee Surg Sports Traumatol Arthrosc* 2012; 20(9):1696-703.
42. Gobbi A, Francisco RA, Lubowitz JH et al. Osteochondral lesions of the talus: randomized controlled trial comparing chondroplasty, microfracture, and osteochondral autograft transplantation. *Arthroscopy* 2006; 22(10):1085-92.
43. Kon E, Filardo G, Di Matteo B et al. Matrix assisted autologous chondrocyte transplantation for cartilage treatment: A systematic review. *Bone Joint Res* 2013; 2(2):18-25.
44. Saris D, Price A, Widuchowski W et al. Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial. *Am J Sports Med* 2014.
45. Basad E, Ishaque B, Bachmann G et al. Matrix-induced autologous chondrocyte implantation versus microfracture in the treatment of cartilage defects of the knee: a 2-year randomised study. *Knee Surg Sports Traumatol Arthrosc* 2010; 18(4):519-27.
46. Crawford DC, DeBerardino TM, Williams RJ, 3rd. NeoCart, an autologous cartilage tissue implant, compared with microfracture for treatment of distal femoral cartilage lesions: an FDA phase-II prospective, randomized clinical trial after two years. *J Bone Joint Surg Am* 2012; 94(11):979-89.
47. Zeifang F, Oberle D, Nierhoff C et al. Autologous chondrocyte implantation using the original periosteum-cover technique versus matrix-associated autologous chondrocyte implantation: a randomized clinical trial. *Am J Sports Med* 2010; 38(5):924-33.

48. Saris DB, Vanlauwe J, Victor J et al. Characterized chondrocyte implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial versus microfracture. *Am J Sports Med* 2008; 36(2):235-46.
49. Saris DB, Vanlauwe J, Victor J et al. Treatment of symptomatic cartilage defects of the knee: characterized chondrocyte implantation results in better clinical outcome at 36 months in a randomized trial compared to microfracture. *Am J Sports Med* 2009; 37 Suppl 1:10S-19S.
50. Kon E, Filardo G, Berruto M et al. Articular cartilage treatment in high-level male soccer players: a prospective comparative study of arthroscopic second-generation autologous chondrocyte implantation versus microfracture. *Am J Sports Med* 2011; 39(12):2549-57.
51. American Academy of Orthopaedic Surgeons. Clinical practice guideline on the diagnosis and treatment of osteochondritis dissecans. 2010. Available online at: [http://www.aaos.org/research/guidelines/OCD\\_guideline.pdf](http://www.aaos.org/research/guidelines/OCD_guideline.pdf). Last accessed March, 2011.
52. National Institute for Health and Clinical Excellence. The use of autologous chondrocyte implantation for the treatment of cartilage defects in knee joints. Technology Appraisal Guidance No. 89. 2005. Available online at: <http://www.nice.org.uk/page.aspx?o=TA089guidance>. Last accessed March, 2011.